Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP
This page from TradingView displays financial information for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its Enterprise Value to EBITDA forward metric. The content indicates that the market is currently closed, and no trades have occurred for this stock.
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP
This page provides financial data for Enanta Pharmaceuticals, Inc. (GETTEX:9EP), specifically focusing on its enterprise value to EBIT forward. The content is hosted on TradingView, a platform offering various financial tools and market data, and includes legal disclaimers about data sources and copyrights.
Form 424B5 Enanta Pharmaceuticals Inc For: 2 July By Investing.com
This article announces the filing of Form 424B5 for Enanta Pharmaceuticals Inc. on July 2nd. It provides basic information about the filing and includes irrelevant market data and news headlines, typical of an Investing.com article.
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This page on TradingView.com focuses on the "Price to sales forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It provides financial data and an overview of the company's valuation, indicating information about the market performance and financial health of Enanta Pharmaceuticals. The content primarily serves as a financial data point for investors and analysts.
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell Small Cap Comp Growth Benchmark, as well as the Russell 2500 Growth and Russell 2000 Growth Benchmarks. This inclusion indicates recognition of the company's growth potential within the small-cap market. The article also provides a brief overview of Enanta Pharmaceuticals, including its focus on antiviral and immunology drug discovery and development.
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark
Enanta Pharmaceuticals, Inc. (NasdaqGS: ENTA) has been added to the Russell 3000E Growth Benchmark. The clinical-stage biotechnology company, focused on virology and immunology, saw its stock rise by 4.09% to 14.00 USD. This inclusion highlights the company's growth potential and ongoing developments, including its RSV clinical programs and patent dispute with Pfizer.
Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry
This article is a statement of changes in beneficial ownership of securities for Enanta Pharmaceuticals, specifically pertaining to Director Vance Terry. It is a regulatory filing indicating transactions related to his holdings in the company.
Enanta Pharmaceuticals | SCHEDULE 13G/A: Others
This article indicates that a SCHEDULE 13G/A filing related to Enanta Pharmaceuticals (ENTA) has been submitted into the public record. The filing is categorized under "Others," suggesting a beneficial ownership report from a passive investor or another type of filer.
Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP
This article focuses on the enterprise value to revenue forward for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP). It lists the company's trading information on the Tradegate Exchange, indicating that the market is currently closed with no trades. The piece is primarily a financial data point presented on the TradingView platform.
Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA)
This article provides financial actuals and estimates for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), including stock price performance, analyst forecasts, earnings, revenue, and market capitalization. It highlights the company's historical stock prices, volatility, and upcoming earnings report.
Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This article provides the "Price to book forward" for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It is a finance-related snippet from TradingView, indicating a focus on financial metrics for the company. The content itself is minimalist, primarily showcasing the title and context within the TradingView platform.
Enanta Pharmaceuticals, Inc. Actuals & Estimates (FWB:9EP)
This article provides an overview of Enanta Pharmaceuticals, Inc. (FWB:9EP) financials, analyst forecasts, and historical stock performance. It includes details on past earnings, revenue, EBITDA, and provides predictions for future financial results, noting that the company does not pay dividends. The report also lists the company's next earnings release date and key stock price milestones.
ENTA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Enanta Pharmaceuticals, Inc. (ENTA) stock, including analyst price targets, historical performance, and key financial data. Eight analysts have provided 1-year price forecasts, with a maximum estimate of $32.00 and a minimum of $14.00. The company's stock has shown significant increases over the past year and the article details its market capitalization, earnings, revenue, and upcoming earnings report.
Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
This article displays the "Price to earnings forward" metric for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). It presents financial data for the company, accessible through TradingView, and includes general market and company information. The content primarily focuses on the stock's financial performance metric without providing detailed analysis.
Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP
This article provides financial information for Enanta Pharmaceuticals, Inc. (TRADEGATE:9EP), specifically focusing on its price to book forward value. The data is available through TradingView, which aggregates market and reference data from various providers.
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) saw its shares rally 5.2% after its partner, AbbVie, received European Commission approval for Maviret to treat acute hepatitis C. Enanta receives royalties from Maviret's sales. Despite the immediate bump, the stock's future strength is uncertain as consensus EPS estimates for the upcoming quarter have remained unchanged, and the stock currently holds a Zacks Rank #3 (Hold).
EC approves label expansion for Enanta’s Maviret in acute HCV infection
The European Commission (EC) has approved Maviret (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged three years and older. This approval makes Maviret the only treatment available in the EU for both acute and chronic HCV infection. Developed in collaboration with AbbVie, shares of Enanta Pharmaceuticals (Nasdaq: ENTA) rose 5.2% following the announcement.
Form 8K Enanta Pharmaceuticals Inc For: 23 June
This article reports on an SEC Form 8K filing by Enanta Pharmaceuticals Inc for June 23. It states that the information provided is not necessarily real-time or accurate and advises readers about the high risks associated with trading financial instruments and cryptocurrencies. The article reiterates that Fusion Media is not liable for any losses incurred from trading based on its information.
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com
This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. The filing is an important regulatory disclosure for public companies. The article provides the title of the filing and mentions the company's stock symbol ENTA, which had a 4.09% increase.
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event
Enanta Pharmaceuticals, Inc. (ENTA) reported via an 8-K filing that the United States Court of Appeals for the Federal Circuit affirmed a prior summary judgment ruling, invalidating Enanta's U.S. Patent No. 11,358,953. This patent was related to Pfizer Inc.'s COVID-19 antiviral, Paxlovid, thereby upholding a December 2024 decision. The ruling effectively removes the possibility of Enanta seeking damages against Pfizer based on this specific patent.
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com
This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. It notes a 5.16% increase in the company's stock symbol ENTA. The filing is typical for disclosing significant events to shareholders and the SEC.
Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com
This article reports that Enanta Pharmaceuticals Inc. filed a Form 8K on June 23. The filing is brief, containing only the headline and the company's stock symbol ENTA which saw a 1.97% decline. The article appears to be an automated notification of the SEC filing rather than an in-depth analysis.
CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application
The U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed the invalidity of Enanta Pharmaceuticals, Inc.'s U.S. Patent 11,358,953 due to a lack of written description support in its provisional application. This decision means the patent cannot claim the earlier priority date, leading to anticipation by Pfizer's prior disclosure of nirmatrelvir. The court ruled that the provisional did not adequately disclose a one-carbon alkyl group, which was crucial for the claimed invention.
H.C. Wainwright reiterates Enanta stock rating on FDA alignment
H.C. Wainwright maintained a Buy rating and $20.00 price target for Enanta Pharmaceuticals (NASDAQ:ENTA) following the FDA's alignment on zelicapavir, which significantly reduces regulatory uncertainty for the RSV drug. Enanta also announced plans for late-stage clinical trials for zelicapavir and a Phase 1 trial for EDP-978, while a patent infringement case against Pfizer awaits oral arguments.
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Enanta Pharmaceuticals announced that its partner AbbVie received European Commission approval for MAVIRET® (glecaprevir/pibrentasvir) to treat acute Hepatitis C Virus (HCV) infection in adults and children aged 3 years and older. This makes MAVIRET the only EU-approved treatment for both acute and chronic HCV. The approval is based on Phase 3 study data showing high efficacy and a favorable safety profile, supporting earlier treatment to reduce transmission and liver complications.
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET
The European Commission has approved MAVIRET (glecaprevir/pibrentasvir), developed by AbbVie with glecaprevir discovered by Enanta Pharmaceuticals, for treating acute Hepatitis C Virus (HCV) infection in adults and children aged 3 and older. This makes MAVIRET the only treatment approved in the EU for both acute and chronic HCV, enabling earlier intervention and reducing transmission. The approval was based on Phase 3 study data demonstrating high efficacy and a favorable safety profile for eight-week MAVIRET treatment in acute HCV patients.
Enanta Pharmaceuticals (ENTA) reports Q2 loss, lags revenue estimates
The article reports that Enanta Pharmaceuticals (ENTA) experienced a loss in its second fiscal quarter and did not meet revenue estimates. This suggests a challenging period for the company, potentially impacting its short-term financial outlook.
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating for Enanta Pharmaceuticals (ENTA.US), maintaining a target price of $20. This indicates a continued positive outlook from the analyst firm on the company's stock performance.
Why (ENTA) Price Action Is Critical for Tactical Trading
This article from Stock Traders Daily discusses the critical price action for Enanta Pharmaceuticals Inc. (ENTA) for tactical trading, noting positive near-term sentiment despite a weak mid-term bias within a long-term strength context. It provides detailed AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Enanta Pharmaceuticals Inc (ENTA), highlighting its current valuation score of 8.22, which ranks 99 out of 157 in the Pharmaceuticals industry. It notes the company's P/E ratio is -4.88, significantly below its recent high and above its recent low. However, key metrics like P/B, P/S, and P/CF data have not yet been disclosed by the company.
Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis
Enanta Pharmaceuticals Inc (ENTA) has a weak financial status with a score of 7.73, ranking 102 out of 157 in the Pharmaceuticals industry, despite high operating efficiency. The company recently reported a 14.96% year-over-year revenue increase to $17.16M and a 42.19% year-over-year net profit increase. The analysis highlights its financial health metrics across profitability, operational efficiency, growth potential, and shareholder returns.
Enanta Pharmaceuticals stock rises on RSV drug trial plans
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) saw its shares rise after announcing plans to advance its RSV drug, zelicapavir, into late-stage clinical trials. The company will initiate a registrational Phase 2b/3 trial for high-risk adults in Q4 2026 and a Phase 2b trial for pediatric patients in Q3 2026, with topline data for both expected in 2027. This decision follows positive results from a previous Phase 2 trial and a successful End-of-Phase 2 meeting with the FDA.
Enanta Pharmaceuticals Inc (ENTA) Institutional Confidence
The article analyzes the institutional confidence in Enanta Pharmaceuticals Inc (ENTA), noting its high institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. Institutional shareholding proportion increased by 11.57% quarter-over-quarter, reaching 91.33%. James Simons is the largest institutional shareholder, with other major firms like Janus Henderson Investors and BlackRock Institutional Trust Company significantly increasing their holdings.
Enanta Pharmaceuticals Inc (ENTA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Enanta Pharmaceuticals Inc (ENTA) has an earnings forecast score of 8.29, ranking 44th in the Pharmaceuticals industry. Analysts have an average price target of $20.00, with a consensus "Buy" rating based on 7 analysts. The company's expected revenue for the next quarter is $17.92M, and its previous quarter's EPS was -$0.42, with an expectation of -$0.45 for the next quarter.
Zelicapavir RSV drug moves into registrational trials at Enanta (ENTA)
Enanta Pharmaceuticals announced it is advancing its RSV antiviral drug zelicapavir into a single registrational Phase 2b/3 trial for high-risk adult outpatients, with topline Phase 2b data expected in 2027. The company also plans a Phase 2b pediatric trial starting in Q3 2026, with data also anticipated in 2027, following positive earlier Phase 2 results. Enanta estimates a significant global market opportunity of over $2 billion for an oral RSV antiviral for children and high-risk adults, with over 3 million potential U.S. patients.
Enanta Pharmaceuticals stock rises on RSV drug trial plans By Investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) shares rose after the company announced plans for late-stage clinical trials of its RSV drug, zelicapivir. The company will initiate a Phase 2b/3 trial for high-risk adults in Q4 2026 and a Phase 2b trial for pediatric patients in Q3 2026, with topline data from both expected in 2027. This advancement follows positive results in a previous Phase 2 trial and Fast Track designation from the FDA.
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncillial Virus (RSV)
Enanta Pharmaceuticals announced the advancement of its zelicapavir program for Respiratory Syncytial Virus (RSV) into a registrational Phase 2b/3 trial for high-risk adults and a Phase 2b trial for pediatric patients. Both trials are expected to initiate in 2026, with topline data anticipated in 2027. This move follows a successful End-of-Phase 2 meeting with the FDA, positioning zelicapavir as a potential first antiviral therapy for RSV.
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Enanta Pharmaceuticals Inc (ENTA), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for detailed financial breakdowns are not yet disclosed by the company, though it does mention a United States revenue of $18.61 million. The page appears to be a financial data portal, indicating a placeholder for more detailed financial disclosures once available.
Enanta Pharmaceuticals Inc (ENTA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Enanta Pharmaceuticals Inc's (ENTA) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and has no recorded stock splits. The page also includes current stock information, financial data, and market performance for ENTA.
Understanding Momentum Shifts in (ENTA)
This article analyzes Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) using AI models to identify momentum shifts. Key findings indicate divergent sentiment across all horizons, suggesting choppy conditions and elevated downside risk due to a lack of long-term support signals. Three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis, to help investors navigate ENTA's performance.
Avoiding Lag: Real-Time Signals in (ENTA) Movement
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is showing weak near and mid-term sentiment, challenging a previously strong long-term outlook. Despite a lack of clear price positioning signals and elevated downside risk, AI models have generated distinct trading strategies including long, breakout, and short positions based on different risk profiles and time horizons. The analysis emphasizes real-time signals, risk management, and multi-timeframe insights for investors.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2026
Enanta Pharmaceuticals announced that its President and CEO, Jay R. Luly, Ph.D., and Chief Product Strategy Officer, Tara L. Kieffer, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The clinical-stage biotechnology company, focused on small molecule drugs for viral infections and immunological diseases, will provide a live webcast of the event on its investor relations website. A replay will also be available for at least 30 days following the presentation.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals, Inc. announced that its President and CEO, Jay R. Luly, and Chief Product Strategy Officer, Tara L. Kieffer, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 4, 2026, at 11:40 a.m. ET in New York, NY, and a live webcast will be available on Enanta's website. The company focuses on developing small molecule drugs for viral infections and immunological diseases, with ongoing programs in RSV and inflammatory diseases.
Discipline and Rules-Based Execution in ENTA Response
The article discusses the investment opportunity in Enanta Pharmaceuticals Inc. (NASDAQ: ENTA), highlighting a mid-channel oscillation pattern and a significant 56.7:1 risk-reward setup targeting a 17.1% gain. It provides three distinct AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for different risk profiles, along with multi-timeframe signal analysis indicating weak near-term sentiment but strong long-term potential.
Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives
Enanta Pharmaceuticals (ENTA) reported improved Q2 2026 results, with a narrowed basic EPS loss of US$0.45 and revenue of US$17.2 million. The company's trailing twelve-month net loss decreased by US$9.6 million, and quarterly losses have been consistently smaller compared to previous periods. Despite ongoing unprofitability and shareholder dilution, the stock trades at a lower P/S ratio than the industry average, with analysts expecting 17.6% annual revenue growth.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Enanta Pharmaceuticals (NASDAQ: ENTA) released Q2 results, with revenues meeting analyst predictions at US$17m and statutory losses being 7.7% smaller than expected at US$0.45 per share. Analysts forecast revenues of US$66.9m for 2026, a 3.3% decline, and increased per-share losses to US$2.21, reflecting mixed sentiment. Despite these adjustments, the consensus price target remains US$20.14, indicating that the business is performing largely as expected.
Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
The article, titled "Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA," appears to be a stub or a section heading from a financial data platform like TradingView. It indicates a focus on the number of shareholders for the company, Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), within the Pharmaceuticals: Major segment.
ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary
Enanta Pharmaceuticals Inc. reported its fiscal Q3 2026 results, showing revenue of $17.16M and a narrowed net loss compared to the previous year. This improvement was attributed to increased royalty revenue from MAVYRET/MAVIRET sales and progress in its RSV and immunology programs, while the company maintains a strong liquidity position extending into fiscal 2029.
Number of shareholders of Enanta Pharmaceuticals, Inc. – BX:9EP
This article provides the title "Number of shareholders of Enanta Pharmaceuticals, Inc. – BX:9EP" but lacks any further content regarding the actual number of shareholders. It appears to be a stub or a placeholder for financial data related to Enanta Pharmaceuticals (9EP) on the BX Swiss exchange, with various navigational and footer information from TradingView.
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event
Enanta Pharmaceuticals Inc. filed an 8-K report detailing a material event and released its financial results for the fiscal second quarter ended March 31, 2026. The company announced $17.2 million in total revenue, driven by royalty income from MAVYRET®/MAVIRET®, and reported a net loss of $13.1 million. Enanta highlighted progress in its clinical pipeline, including dosing in a Phase 1 trial for EDP-978 for chronic urticaria, advancing zelicapavir for RSV, and preparing IND filings for other immunology programs, while maintaining a strong cash position expected to fund operations into fiscal 2029.
